Categories: News

Modular Medical Announces Addition to the Russell Microcap(R) Index

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

SAN DIEGO, CA / ACCESSWIRE / June 3, 2024 / Modular Medical, Inc. (NASDAQ:MODD) (“Modular Medical”), a development-stage, insulin delivery technology company seeking to launch the next generation of user-friendly and affordable insulin pump technology, today announced that it is set to join the Russell Microcap Index at the conclusion of the 2024 Russell indexes annual reconstitution, effective when the U.S. market opens on July 1, 2024.

Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $10.6 trillion in assets are benchmarked against Russell’s US indexes. Russell indexes are part of FTSE Russell, a leading global index provider.

For more information on the Russell Microcap Index and the Russell indexes reconstitution, go to the “Russell Reconstitution” section on the FTSE Russell website.

About Modular Medical

Modular Medical, Inc. (Nasdaq: MODD) is a development-stage medical device company that intends to launch the next generation of insulin delivery technology. Using its patented technologies, the company seeks to eliminate the tradeoff between complexity and efficacy, thereby making top quality insulin delivery both affordable and simple to learn. Our mission is to improve access to the highest standard of glycemic control for people with diabetes taking it beyond “superusers” and providing “diabetes care for the rest of us.”

Modular Medical was founded by Paul DiPerna, a seasoned medical device professional and microfluidics engineer. Prior to founding Modular Medical, Mr. DiPerna was the founder (in 2005) of Tandem Diabetes and invented and designed its t:slim insulin pump. More information is available at https://modular-medical.com.

All trademarks mentioned herein are the property of their respective owners.

CONTACT:

Jeb Besser
Chief Executive Officer
Modular Medical, Inc.
+1 (617) 399-1741
IR@modular-medical.com

SOURCE: Modular Medical, Inc.

View the original press release on accesswire.com

Staff

Recent Posts

Clymb Clinical Introduces TFL Viewer: A Cutting-Edge Platform for Collaborative Clinical Trial Reporting

BURLINGTON, Mass., May 22, 2025 /PRNewswire/ -- Clymb Clinical is proud to announce the launch…

29 minutes ago

AbbaDox Named a Top South Florida Workplace for Third Year in a Row

A people-first culture continues to earn national and regional recognition BOCA RATON, Fla., May 22,…

29 minutes ago

Rodan + Fields Unveils “Love What You See” – A Campaign Honoring Personal Skincare Journeys

New purpose-driven brand campaign highlights the science behind R+F's skincare and the visible results it…

29 minutes ago

Xentria Launches Xturnpoint to Fuel Early-Stage Therapeutic Innovation, Expands Headquarters to Support Growth

Xentria introduces Xturnpoint, a venture partnering studio to support early-stage therapeutic innovators with an exclusive…

29 minutes ago

Pictor Establishes U.S. Headquarters and Scales Operations, Revolutionizing Proteomics Testing Amid Regulatory Shift

CARLSBAD, Calif., May 20, 2025 /PRNewswire/ -- Pictor, a global leader in multiplex proteomics solutions,…

29 minutes ago